Cicada COVID Variant (BA.3.2): Symptoms, Spread, Vaccine Effectiveness and Latest Updates

The Cicada variant (BA.3.2) is a newly re-emerging strain of COVID-19, gaining attention in 2026 due to its unusual pattern of disappearance and resurgence.

First detected in South Africa in 2024, this variant faded temporarily but has now reappeared in Europe and the United States, raising concerns among global health experts.

The name “Cicada” comes from its behaviour, similar to cicada insects that remain dormant and reappear periodically.

Scientific Overview: Mutations and Structure of Cicada COVID Variant (BA.3.2)

The Cicada variant belongs to the Omicron lineage, which first emerged in 2021. However, it stands out due to:

• 70–75 mutations in the spike protein
• Higher mutation load than many previous Omicron subvariants
• Enhanced ability to evade immune responses

Why Spike Protein Matters:

• It is the part of the virus that attaches to human cells
• It is the primary target of vaccines and antibodies

Implication:
More mutations → Greater immune escape → Potential reinfections

Also Check: List of COVID Sub-variants

Global Spread and Current Status (2026)

The Cicada variant is not yet dominant globally but is spreading steadily:

• Responsible for ~30% of COVID cases in parts of Europe
• Detected across multiple U.S. states
• Limited but growing surveillance data

Key Challenge:

Post-pandemic fatigue has reduced:

• Testing rates
• Reporting systems
• Genome sequencing

This makes tracking new variants like Cicada more difficult

Is Another Lockdown Coming Amid Energy Crisis?

Symptoms of Cicada Variant

The symptoms of BA.3.2 are similar to previous Omicron variants:

• Sore throat
• Fever or chills
• Persistent cough
• Headache
• Body aches
• Runny nose

Duration:

• Typically lasts 3–7 days
• Mild to moderate in most cases

Important:
Symptoms overlap with flu → Testing is essential for confirmation

Vaccine Effectiveness Against Cicada Variant

Current COVID vaccines—especially updated ones targeting Omicron strains like JN.1—still provide protection.

What the Data Suggests:

• Protection against severe illness & hospitalisation
• Reduced ability to prevent infection or mild illness

Why Reduced Effectiveness?

• Spike protein mutations allow the virus to partially escape immunity

Expert Insight:
Vaccines are designed primarily to reduce severity, not eliminate infection risk

Who is at Higher Risk?

Certain groups remain vulnerable:

• Elderly individuals (especially 75+)
• People with weak immune systems
• Individuals not up-to-date with vaccinations

Key Trend:

Most hospitalised COVID patients are not fully vaccinated or boosted

Do COVID Tests Detect Cicada Variant?

• Most rapid antigen and PCR tests:
  • Target stable regions of the virus
  • Likely remain effective

However:

• Scientific data is still evolving
• Continuous validation is needed

Does Cicada Cause More Severe Disease?

As of now:

• No confirmed evidence of higher severity
• No clear increase in mortality

But:

• High mutation count raises concern
• Future dominance depends on:
  • Transmission rate
  • Immune escape ability

Scientists are still studying real-world data

Why Cicada Variant Matters in 2026

The emergence of BA.3.2 highlights key global health realities:

1. COVID is Becoming Endemic

• Regular waves expected
• Seasonal peaks (summer & winter)

2. Mutation is Continuous

• Virus evolution is ongoing
• New variants will keep emerging

3. Surveillance Systems are Weakening

• Reduced testing and reporting
• Greater reliance on self-testing

Sharing is caring!